Fig. 4

Forest plot of meta-analysis of progression-free survival (PFS) based on ECOG performance status between patients receiving immunotherapy plus chemotherapy (ICT) and CT alone. Immunotherapy mainly consisted of PD-1/PD-L1 inhibitors